Neurotech International (ASX:NTI) has announced positive results from its recently completed 28-day Good Laboratory Practice oral toxicology studies evaluating its lead drug candidate NTI164.
Neurotech says NTI164 shows positive tolerability in key preclinical toxicology studies
May 5, 2025 Australian Biotech
Latest Video
New Stories
-
Queensland cardiac experts back a new plan to stop the second heart attack
September 18, 2026 - - Latest News -
We have one of Australia's answers to 'MFN' and people will die as a result
September 18, 2026 - - Latest News -
Is the fairest part of our medicines access system delivered overseas?
September 18, 2026 - - Latest News -
Mayne Pharma bets on an untapped corner of the menopause market
September 17, 2026 - - Latest News -
Genomic testing to reach more patients with hard to treat cancers
September 17, 2026 - - Latest News -
Eight women named finalists for 2026 Marie Krogh Young Women in Science Prize
September 17, 2026 - - Latest News -
'Your success makes you a target and take it as a compliment'
September 16, 2026 - - Latest News
